Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

NASDAQ Biotech 

WKN:  ISIN:  
Markt oder Branche auswählen:

Aktuelle News zu Aktien im NASDAQ Biotech

  • 24 h
  • 7 Tage
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
Zeit Aktuelle Nachrichten
Sprache:  Alle DE EN
LeserMedien
DoGenmab expands US headquarters, plots 300 hires amid launch of AbbVie-partnered lymphoma med Epkinly5
DoCentessa Pharmaceuticals GAAP EPS of -$0.381
DoAcelyrin GAAP EPS of -$5.431
DoCentessa Pharmaceuticals plc - S-8, Securities to be offered to employees in employee benefit plans1
DoVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)1
DoATAI Life Sciences N.V. - 10-K, Annual Report1
DoACELYRIN, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
DoBlackstone Investing Up To $750 Million In Moderna6
DoCentessa Pharmaceuticals plc - 8-K, Current Report1
DoCentessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023265Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024Orexin Agonist Program:...
► Artikel lesen
DoLiquidia gains after court win in patent dispute with United Therapeutics2
DoZymeworks Inc. - 8-K, Current Report1
DoArdelyx, Inc. Reports Employment Inducement Grants1
DoRevolution Medicines, Inc.: Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 20241
DoEnliven Therapeutics, Inc.: Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 20241
DoGalapagos NV: Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings196Publication of annual report for financial year 2023Annual Shareholders' Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board membersExtraordinary Shareholders'...
► Artikel lesen
DoACELYRIN, Inc. - 8-K, Current Report1
DoReneo Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
DoACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights-
DoCoherus BioSciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans3
Seite:  Weiter >>